BIO CEO Warns U.S. Could Lose Biotech Leadership to China Within Two Years
GeoVax Labs calls for urgent policy action following Biotechnology Innovation Organization CEO John Crowley's warning that China could overtake U.S. biotech leadership within two years, highlighting the need for vaccine platform diversity, onshoring manufacturing, and protecting immunocompromised populations.
The United States faces the potential loss of its global biotechnology leadership position to China within the next two years, according to testimony delivered by Biotechnology Innovation Organization CEO John Crowley at a Senate HELP Committee hearing. GeoVax Labs, Inc. responded to this warning by calling for immediate Congressional and Administration action to secure America's competitiveness and biosecurity through strategic investments and policy reforms.
David A. Dodd, Chairman and CEO of GeoVax, stated that Crowley's testimony should serve as a clear call to action. "John Crowley sounded the alarm: America could lose its biotech leadership within two years. Competitiveness is national security," Dodd emphasized. "Congress and the Administration must move quickly to diversify vaccine platforms, bring manufacturing home, and prioritize high-risk populations."
GeoVax outlined six priority actions for policymakers to address the emerging threat. The company called for diversifying vaccine platforms beyond current reliance on mRNA technology by funding MVA and other multi-antigen, next-generation technologies. Onshoring advanced manufacturing with continuous cell-line vaccine production and U.S.-based fill/finish capacity represents another critical priority. Protecting National Institutes of Health funding that fuels the biotech innovation pipeline and modernizing FDA pathways with expanded use of immuno-bridging and expedited programs for high-risk populations were also identified as essential measures.
The company further recommended expanding incentives such as priority review vouchers for biodefense products and pairing China guardrails with U.S. investment to ensure scale-up and resilience at home. These comprehensive measures aim to address both immediate competitiveness concerns and long-term strategic positioning in the global biotech landscape.
GeoVax highlighted two near-term solutions already in development. The company's GEO-MVA Mpox/smallpox vaccine is targeted to be manufactured on a continuous cell line, positioning the U.S. with a critical supply source to replenish the Strategic National Stockpile and address global demand shortfalls. Additionally, GEO-CM04S1, a multi-antigen COVID-19 vaccine, is specifically designed for immunocompromised individuals who remain vulnerable despite current vaccine options.
"These are not distant concepts - we have programs ready now," Dodd added. "Our GEO-MVA Mpox/smallpox vaccine can immediately strengthen national security by adding a U.S. supplier for the stockpile, and our CM04S1 vaccine is uniquely designed to protect the 40+ million immunocompromised Americans who remain at risk. By acting today, policymakers can turn warnings into wins for public health and U.S. leadership."
For more information about the company's clinical trials and development programs, visit https://www.geovax.com. The urgency of these policy actions reflects the critical window of opportunity to maintain American leadership in biotechnology while addressing pressing public health needs and national security concerns.